The graft-versus-leukemia effect of allogeneic hematopoietic stem cell transplantation (HSCT) has shown that the immune system is capable of eradicating acute myeloid leukemia (AML). This knowledge, along with the identification of the target antigens against which antileukemia immune responses are directed, has provided a strong impetus for the development of antigen-targeted immunotherapy of AML. The success of any antigen-specific immunotherapeutic strategy depends critically on the choice of target antigen. Ideal molecules for immune targeting in AML are those that are: (1) leukemia-specific; (2) expressed in most leukemic blasts including leukemic stem cells; (3) important for the leukemic phenotype; (4) immunogenic; and (5) clinically effective. In this review, we provide a comprehensive overview on AML-related tumor antigens and assess their applicability for immunotherapy against the five criteria outlined above. In this way, we aim to facilitate the selection of appropriate target antigens, a task that has become increasingly challenging given the large number of antigens identified and the rapid pace at which new targets are being discovered. The information provided in this review is intended to guide the rational design of future antigen-specific immunotherapy trials, which will hopefully lead to new antileukemia therapies with more selectivity and higher efficacy.
INTRODUCTION
The graft-versus-leukemia (GvL) effect associated with allogeneic hematopoietic stem cell transplantation (HSCT) is one of the most salient examples of the potential the immune system possesses to eradicate acute myeloid leukemia (AML). Although our knowledge of the role of the immune system in the control of AML is still evolving, it is well established that AML cells, like many other cancer cells, display tumor antigens that can trigger antileukemia immune responses. 1, 2 In the two decades after the discovery of the first tumor-associated antigen (TAA) in melanoma, a considerable number of AML-related antigens have been characterized. This has fueled the development of antigen-directed immunotherapy approaches for AML, which can be separated into two main strategies: 'active' specific immunotherapy (that is, antigen-targeted vaccination) and 'passive' immunotherapy (that is, adoptive transfer of antigen-reactive T cells, as in the context of allogeneic HSCT or donor lymphocyte infusions (DLI)). 3 With an ever-increasing number of TAAs being identified, the selection of appropriate target antigens in the design of immunotherapy protocols is becoming a daunting but necessary task because the efficacy of antigen-specific immunotherapy is contingent on the use of an immunocompetent target antigen that can be recognized by the immune system and elicit protective antitumor immune reponses. 4 Recently, the Translational Research Working Group of the National Cancer Institute specified a number of criteria for evaluating the suitability of a given tumor antigen for therapeutic application. 4 If we apply these criteria to the context of AML, the 'ideal' target antigen for AML immunotherapy would meet the following requirements: (1) be expressed in leukemic cells with minimal to no expression in normal tissues; (2) display high and homogeneous expression levels in most to all leukemic cells, including leukemic stem cells (LSCs); (3) play a defined oncogenic role; (4) possess strong immunogenic properties; and (5) demonstrate clinical utility. 4 Here, in an effort to guide the selection of candidate target antigens, we will provide an overview of all of the currently identified AML-related antigens and review their applicability for AML immunotherapy according to the selection criteria outlined above. Table 1 presents a list of AML-related antigens, divided into four categories according to their expression patterns in nonmalignant and leukemic cells: leukemia-specific antigens (LSAs), leukemia-associated antigens (LAAs), cancer-testis antigens (CTAs) and ubiquitous antigens. Because of their leukemia-restricted expression pattern, LSAs are considered to be the most appropriate targets for immunotherapeutic intervention. 4 This category of antigens contains a number of fusion proteins, which are unique leukemia-specific proteins that arise from defined chromosomal translocations in AML cells. Although more than 200 chromosomal translocations have been identified in AML, only a select minority are known to give rise to antigenic proteins. Among these are the fusion proteins AML1-ETO, 5 DEK-CAN 6 and promyelocytic leukemia-retinoic acid receptor a (PML-RARa), 7, 8 resulting from the t(8;21), t(6;9) and t(15;17) chromosomal translocations, respectively. 9 In addition, gene mutations occurring in tumor cells may result in the formation of mutant tumor-specific proteins. If recognized by the immune system, these mutant proteins can serve as tumor-specific antigens. 4 Two examples of such mutations in AML cells are internal tandem duplications (ITD) of the FMS-like tyrosine kinase 3 gene (Flt3) and mutations in the nucleophosmin 1 (NPM1) gene. The mutant proteins arising from these gene mutations are known to act as LSAs. [10] [11] [12] The majority of antigens have been characterized as LAAs, that is, they are expressed by both normal and leukemic cells. Hence, autoimmunity could be a logical consequence of targeting TAAs. To anticipate the type of autoimmune reactions when using such antigens for targeted immunotherapy, it is of crucial importance to define their normal tissue distribution. For example, the TAA G250/carbonic anhydrase IX, which has also been identified as a LAA, is known to be expressed in the bile duct epithelium, accounting for the reported risk of developing cholestasis during G250-targeted T-cell therapy. 13 Nevertheless, the risk of autoimmunity with TAA-specific immunotherapy is generally considered to be theoretical because of the natural immunological tolerance towards self-antigens. In view of this, one can speculate whether TAAs could qualify as valid candidate targets for immunotherapy. However, dysregulated overexpression of TAAs in tumor cells may allow the immune system to accurately discriminate these cells from their normal counterparts, supporting the immunotherapeutic utility of TAAs despite their self-antigenic nature. The LAA Wilms' tumor protein 1 (WT1) serves as a particularly illustrative example of this.
CRITERION 1: LEUKEMIA SPECIFICITY
14 WT1 is highly overexpressed in the majority of AML cases, but is also expressed, albeit at low level, in various normal tissues, such as gonads, kidney and the hematopoietic system. 15, 16 On-target toxicity against these tissues has not been observed in studies of WT1-directed immunotherapy, confirming that tissues with physiological expression of WT1 are spared from immune attack. 14 Moreover, certain LAAs can be viewed as relatively leukemiaspecific, thus limiting problems associated with autoimmunity or tolerance. This is the case for LAAs possessing highly restricted levels of expression in normal cell types, such as human telomerase reverse transcriptase (hTERT) 17 and survivin. 18 In view of their role in promoting unrestrained cell growth and survival, it is not surprising to find the overexpression of these proteins in a wide variety of human cancers and the absence of expression in normal, non-dividing or terminally differentiated cells. 18 Their relatively restricted expression in normal tissues, along with their abundant expression in cancer cells, make hTERT and survivin attractive targets for antigen-specific immunotherapy. Recently, however, some concern has been raised regarding survivin expression in normal, activated T cells, which could cause these cells to become targets of survivinspecific cytotoxic T lymphocytes (CTLs). 19 This phenomenon, known as 'fratricide', could seriously limit the utility of survivin for T-cell-based antigen-specific immunotherapy. 19 T-cell fratricide may also occur with another LAA, the receptor for hyaluronic acidmediated motility (RHAMM), which is also known to be expressed in activated T cells. 20 Oncofetal antigens, such as oncofetal antigen-immature laminin receptor protein (OFA-iLRP), are a distinct category of TAAs that behave in a de facto tumor-specific manner. As their name implies, oncofetal antigens are expressed in malignant tissues and during normal embryonic and fetal development. Their expression is repressed in normal adult tissues, making it unlikely that oncofetal antigen-targeted immunotherapy elicits autoimmunity. 21, 22 ETO, also known as MTG8, which is found to be overexpressed in leukemic cells carrying the t(8;21) chromosomal translocation, 23 is another example of a relatively tumor-specific LAA. Physiological expression of MTG8 appears to be predominantly restricted to the human brain and heart. 23 From an immunotherapeutic point of view, MTG8 expression in these tissues is considered irrelevant because of the immune-privileged status of the central nervous system and the paucity of major histocompatibility complex (MHC) molecules in myocardial tissues, reducing the risk of immune recognition in these tissues. 23 The same consideration applies to LAAs that belong to the CTA family, a large group of immunogenic antigens that are normally expressed only in germ cells of the testes and, to a lesser extent, in ovaries and placental trophoblasts. These tissues are inherently immune privileged, meaning that they are less likely to suffer from autoimmune reactions. As a result, CTAs behave as de facto tumorspecific antigens, which make them particularly amenable for tumor immunotherapy. 24 Preferentially expressed antigen in melanoma (PRAME) is by far the best characterized AMLassociated CTA. 25 However, it is important to note that the normal tissue expression pattern of PRAME is somewhat broader than that of 'classical' CTAs. Low-level PRAME expression has also been observed in the adrenal glands, the endometrium and the pancreas. 26 Moreover, it was recently shown that PRAME-specific T cells may recognize normal kidney epithelial cells and dendritic cells. 27 On the opposite end of the spectrum are ubiquitous antigens, which are not only expressed in leukemic cells, but also in a wide variety of normal human tissues. Examples of such antigens are listed in Table 1 . 26 Owing to their promiscuous and non-leukemiaspecific expression patterns, antigens in this category are considered irrelevant targets for AML immunotherapy and will therefore not be discussed further.
CRITERION 2: FREQUENCY AND PATTERN OF EXPRESSION
Although a certain level of leukemia specificity is mandatory, it will be clear from the above that strict specificity is not an absolute prerequisite in considering the therapeutic suitability of a given antigen. Moreover, the practical implementation of several LSAs seems to be precluded by their limited expression in AML. For example, expression of PML-RARa, Flt3-internal tandem duplication (Flt3-ITD) 11 or mutated NPM1 (ref. 12) is restricted to specific subgroups of AML patients, thus limiting the broad application of these particular antigens for AML immunotherapy.
These examples underscore that, in evaluating potential candidate target antigens for AML immunotherapy, we should not only take into consideration the degree of leukemia specificity, but also whether the antigen is regularly expressed in AML. The antigens listed in Table 1 are further subclassified according to their frequency of expression in AML, using a scale from '1 þ ' (expressed in o25% of primary AML samples) to '4 þ ' (expressed in 475% of samples), as detailed in Table 1 . Data on the expression of CTAs in AML are specified only for cyclin A1, melanoma antigen (MAGE), Per ARNT Sim Domain containing 1 (PASD1), PRAME and renal antigen-1 (RAGE-1), given their relatively frequent expression in AML (expressed in 425% of primary AML samples) and their demonstrated immunogenicity in the setting of AML. Other CTAs, such as BAGE or NY-ESO-1, are not included in Table 1 because these antigens are infrequently expressed and because their immunogenicity has not yet been formally documented in the AML context.
To be considered as a useful target for AML immunotherapy, the antigen should not only be expressed in the vast majority of AML cases, but also in most if not all blast cells of an individual patient. 4 In this regard, expression of the antigen within the LSC compartment is highly desirable. 4 LSCs, which constitute a small subpopulation of leukemic cells and are contained within the CD34 þ CD38 À cell fraction, are responsible for leukemia initiation and relapse because of their potent self-renewal and repopulating capacities. 28 This explains the impetus behind latest efforts to better characterize LSCs and to unravel their gene expression profiles. Majeti et al. 29 compared the gene expression signature of LSCs with that of normal HSCs and identified over 3000 genes with dysregulated expression in LSCs. 29 The published data set also includes several genes encoding proteins that can be recognized by the immune system and act as LAAs, such as 
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LAAs
Importantly, Mcl-1, cyclin B1 and RHAMM expression levels were found to be significantly lower in LSCs compared to normal HSCs. 29 A similar observation was made by Gerber et al. 30 for hTERT, proteinase 3 and survivin, which were shown to be downregulated in chronic myeloid leukemia (CML)-LSCs relative to normal HSCs. 30 Interestingly, in this study, conversion of chronic phase CML to blast crisis-which resembles AML-was paralleled by a further decrease in hTERT, proteinase 3 and survivin expression levels in the LSC compartment. 30 In another large gene expression data set, the LAA-encoding genes cyclin B1, RHAMM, cytochrome P450 1B1 (CYP1B1), nucleolar and spindle-associated protein 1 (NuSAP1), proteinase 3 and survivin were found to be relatively underexpressed in AML-derived LSCs compared to more differentiated CD34 þ CD38 þ leukemic cells. 31 Collectively, these data indicate that LAA-encoding genes may actually be underexpressed in the LSC compartment (Table 1) , rendering the encoded antigens less attractive candidates for LSC-directed immunotherapy.
Targeting of LSCs has become a prime issue for AML therapy in recent years, given the important role of LSCs in the pathogenesis of AML. As shown in synovial sarcoma X breakpoint 2-interacting protein (SSX2IP) 29 and WT1 (Table 1) . 29 The overexpression of WT1 in LSCs has been corroborated by Saito et al., 28 who demonstrated that WT1 was among the most frequently upregulated genes in AML-LSCs relative to normal HSCs. 28 This is consistent with the observation that WT1-specific CTLs were capable of selectively eliminating leukemic cells while sparing normal marrow progenitors. 35 The utility of WT1 for LSC-targeted immunotherapy is further reinforced by its specific overexpression in endosteal LSCs, a subpopulation of LSCs notorious for cell cycle quiescence and resistance to chemotherapeutic agents. 28 
CRITERION 3: ONCOGENICITY
The immunotherapeutic relevance of a given antigen not only depends on its tumor cell specificity and frequency of expression, but also on its role in cancer development, maintenance and/or progression. Targeting such 'pro-malignant' antigens is indeed conceptually attractive, as it may represent an effective way to abrogate tumor-promoting pathways, leading to effective tumor rejection. 4 As shown in Table 1 , numerous LAAs are involved in malignant processes that support AML cell survival, proliferation and differentiation; some of them have even been implicated in leukemogenesis. 36 Apoptosis and proliferation LAAs can tilt the balance between AML cell apoptosis and proliferation in favor of the latter, either by preventing apoptosis or by stimulating cell proliferation. 36 Several of the hitherto characterized LAAs are indeed known to possess potent antiapoptotic properties, including Bcl-2, 36 Bax inhibitor-1 (BI-1), 37 WAF1 , respectively, resulting in an acceleration of the G1/S-phase transition of the cell cycle. 38, 43, 44 BMI1 also represses the expression of p19 ARF and its critical downstream target p53, resulting in a loss of proliferation control. 44 In addition to antiapoptotic genes, WT1 directly modulates the expression of genes that encode components of the cell cycle apparatus, such as cyclin E, which co-regulates the G1/S-phase transition. 42 The recently described AML-related CTA cyclin A1 has also been implicated in the G1/S-phase regulation. 33 Other LAAs, including AurA, 32 36 are predominantly involved in regulating the G2/M transition or the mitotic phase of the cell cycle. AurA, NuSAP1 and RHAMM are also required for mitotic spindle stability. 32, 36, 46, 47 hTERT may confer a proliferative advantage to tumor cells by counteracting telomere shortening. Paradoxically, AML cells usually exhibit decreased expression of hTERT. Nevertheless, the underexpression of hTERT is also thought to contribute to the malignant phenotype of AML cells by causing severe telomere shortening, which in turn leads to genomic instability. 36 
Differentiation
In addition, LAAs may play a role in the pathophysiology of AML by arresting the process of differentiation.
36 PRAME acts as a 'natural' antagonist of the retinoic acid (RA) receptor and disrupts its downstream signaling, thereby preventing normal RA-induced differentiation. 36 Oehler et al. 48 have demonstrated the potential involvement of PRAME in the differentiation arrest that accompanies the conversion of chronic phase CML to blast crisis. 48 A similar observation has been recently made for MUC1. 49 Finally, accumulating evidence also suggests a critical role for the downregulation of WT1 in the process of myeloid differentiation (reviewed in Yang et al. 15 and Sugiyama et al. 16 ).
Leukemogenesis
A direct role for several AML antigens in leukemogenesis has also been established. As shown in Table 1 , a leukemogenic function has been described for all hitherto characterized LSAs. This is not surprising considering the fact that LSAs are formed by genetic alterations (chromosomal translocations or gene mutations) that are causally involved in leukemogenesis. [50] [51] [52] [53] [54] Several LAAs have also been implicated in the multi-step leukemic transformation of hematopoietic progenitor cells, for example, ETO/MTG8, 55 hTERT 56 and the homeobox protein HOXA9. 57 The LAA WT1 may contribute to leukemogenesis by interfering with normal hematopoietic progenitor cell differentiation, which is considered as one of the first critical steps in the leukemic transformation of these cells. 16 In a transgenic mouse model, Nishida et al. 50 also demonstrated the capacity of WT1 to induce leukemia in collaboration with the t(8;21) fusion protein AML1-ETO. 50 The leukemogenic role of WT1 has also been exemplified by its participation in the multiple cooperating events that underlie the progression of myelodysplastic syndromes to AML. 58 Similar to WT1, downregulation of BMI1 has been observed upon normal differentiation of hematopoietic progenitor cells, whereas continuous overexpression accompanies their transformation into leukemic cells. 56 Recently, Yuan et al. 59 confirmed that BMI1 is indispensable for leukemic reprogramming of normal hematopoietic progenitor cells. 59 
CRITERION 4: IMMUNOGENICITY Humoral and cellular immune responses
Effective recognition of the antigen by the immune system is a conditio sine qua non for being considered as a valid immunotherapeutic target. 4 The type of antigen-evoked immune response (for example, humoral, cellular or both) provides important information regarding the immunostimulatory competence of the antigen and its relevance to immunotherapy. Many LAAs have been identified using SEREX, which essentially indicates their capacity to elicit a humoral immune response (Table 1) . Nevertheless, the concept of antigen-specific cancer immunotherapy primarily relies on the induction of a cellular immune response, thus requiring antigen recognition by the T-cell arm of the immune system and induction of antigen-specific CTLs capable of killing antigen-expressing tumor cells.
1 Numerous AML-associated antigens have been reported to contain MHC class I-restricted epitopes that can be recognized by CTLs (Table 1 ). The number of T-cell epitopes per antigen is an important determinant of its immunogenic potential. Longer antigens comprising multiple epitopes are therefore considered highly appropriate for immunotherapeutic applications. 4 Illustrative examples of long LAAs are hTERT, 17 MUC1, 60, 61 proteinase 3, 62 survivin, 63 WT1 (ref. 16) and PRAME (Table 1) . 64 Promiscuity in MHC binding, which refers to the capacity of a single epitope to bind to several different MHC molecules, is another important factor that contributes to the immunogenicity profile of an epitope. 32 For example, AurA 207-215 , a MHC class I-restricted peptide derived from AurA kinase, is known to be presented by HLA-A*0201, HLA-A*0206 and HLA-A*2402. 32 HLA-A*0201 and HLA-A*2402 are the two most common HLA-A types in Caucasian and East Asian populations, respectively, thereby illustrating the potential for broad application of this particular epitope in vaccine trials. 32 A similar observation has been made for two epitopes derived from WT1: WT1 [187] [188] [189] [190] [191] [192] [193] [194] [195] (which binds promiscuously to HLA-A*0201 and HLA-A*0206) 65 and WT1 [235] [236] [237] [238] [239] [240] [241] [242] [243] (which can bind to HLA-A*0201
(ref. 66) and HLA-A*2402 (refs 16,67) ). Finally, it is generally believed that CD4 þ T-cell help is critical for the effective induction and maintenance of antitumoral CTL immunity. 68 Hence, the presence of CD4 þ T-cell 'helper' epitopes within the larger structure of the antigen is a highly desirable immunogenic property. 69 Antigenic peptides presented by MHC class II molecules are usually longer than peptide fragments bound to MHC class I molecules, the latter typically being nine amino acids in length (nonapeptides). 69 To date, few CD4 þ T-cell epitopes have been identified within AML antigens (Table 1) . WT1 is one of the rare examples of a LAA known to include multiple MHC class II-restricted epitopes associated with the induction of AML-specific immunity. 16, 69 Perhaps, the most immunogenic of these epitopes is WT1 , as demonstrated by the capacity of WT1 331-352 peptide vaccination to induce specific CD4 þ T-cell immune responses in nearly 90% of AML patients. 69 It is important to note that this peptide fragment contains another MHC class IIrestricted epitope, WT1 332-347 , which has a promiscuous MHCbinding nature and can be recognized by a broad range of HLA-DR and HLA-DP molecules. 16 This peptide sequence also encompasses the HLA-DP5-restricted WT1 337-347 epitope 70 as well as the WT1 333-347 epitope, which can be recognized by CD4 þ regulatory T cells in the context of HLA-DR4. 71 Other WT1 helper epitopes with direct relevance to AML immunotherapy are WT1 427-445 and WT1 [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] . 69 The latter contains another immunogenic CD4 þ T-cell epitope, WT1 [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] , and the HLA-A*0201-restricted CD8 þ T-cell epitope, WT1 126-134 , 16 and is thus capable of stimulating a combined CD8 þ /CD4 þ WT1-specific T-cell immune response. 69 In vivo immunogenicity The ultimate proof of the immunogenicity of a given antigen rests on the demonstration of antigen-specific immunity in vivo. 4 Evidently, the best and most direct evidence in this regard comes from clinical vaccine trials. 4 At present, only a few LAAs have entered the clinical trial stage. WT1 is among the most advanced targets for AML immunotherapy, as reflected by the relatively large number of WT1-targeted vaccine trials undertaken in patients with AML (reviewed in Van Driessche et al. 14 ) . These studies, including WT1 peptide and WT1-targeted dendritic cell vaccine trials, have unequivocally established that CD8 þ T-cell immune responses specific to WT1 can be induced by active immunization in a substantial number of AML patients. 14 In those patients, multiple WT1 CTL epitopes have been recognized as immunogenic (including WT1 [37] [38] [39] [40] [41] [42] [43] [44] [45] , WT1 [126] [127] [128] [129] [130] [131] [132] [133] [134] , WT1 [187] [188] [189] [190] [191] [192] [193] [194] [195] and WT1 [235] [236] [237] [238] [239] [240] [241] [242] [243] ), demonstrating the excellent in vivo immunostimulatory potential of WT1 (Table 1) . 14, 72 This is further supported by the capacity to induce WT1-specific CD4 þ helper T-cell immunity in patients with AML through active immunization. 69 High in vivo immunogenicity has also been observed for RHAMM. In a phase I clinical trial of vaccination with the immunogenic RHAMM 165-173 epitope, Schmitt and coworkers 47 identified an increase in the frequency of circulating RHAMM-tetramer þ CD8 þ T cells in two out of three AML patients following vaccination. These CTLs were able to induce the selective lysis of autologous RHAMM-expressing AML blasts, confirming the functionality of the vaccine-elicited immune response. 47 Similar results have been obtained with PR1, a nonameric HLA-A*0201-restricted peptide derived from proteinase 3 (amino acids (aa) 169-177). 73 The Molldrem group at the MD Anderson Cancer Center was the first to test the immunogenicity of PR1 peptide vaccination in a mixed cohort of patients with AML, CML and myelodysplastic syndromes. 74 Vaccine-induced immunity, defined as a X2-fold increase in peripheral blood PR1-specific CTLs, was observed in about half of the vaccinated patients. 74 Using a multi-peptide vaccine composed of PR1 and WT1 126-134 , Rezvani et al. 73 were able to provoke a PR1-specific CD8 þ T-cell immune response in all five included patients with AML. 73 Although peptide vaccine trials targeting hTERT have not yet been reported in AML patients, the development of hTERT-specific cellular immunity has been reported in two dendritic cell-based vaccine trials, one trial using hTERT mRNA-electroporated dendritic cells 75 and another using dendritic cells loaded with apoptotic AML blasts. 76 Similarly, Li et al. 77 demonstrated the possibility of eliciting CD8 þ T cells against an immunodominant epitope of PRAME (PRA 300-309 ) by immunizing AML patients with leukemic cell-derived dendritic cells expressing the full leukemic antigen repertoire. 77 The in vivo immunogenicity of several LAAs has also been validated in the setting of allogeneic HSCT. This is reflected by the emergence of antigen-specific CD8 þ T cells in the peripheral blood of AML patients following transplantation. Such CTL responses have been reported against a broad range of AML-related tumor antigens, including HOXA9 (HOXA9 146-154 27, 62 and RAGE-1 (RAGE-1 [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] ) (Table 1) . 79 NuSAP1 has been identified as a target of humoral immunity following allogeneic HSCT. 46 Cellular and/or humoral immune reactivity has been observed against the LAAs CML28, 80 CML66 (refs 81,82) and BMI1 (ref. 83) in allotransplanted CML patients. In addition to LAAs and CTAs, immune responses after HLA-matched allogeneic HSCT might also be directed toward minor histocompatibility antigens (mHAgs). 84 mHAgs constitute a group of peptides derived from self-proteins that, when complexed to MHC molecules, can serve as target structures for T-cell alloimmunity following allogeneic HSCT or DLI. 3 Disparities in mHAgs between the donor and recipient, caused by genetic polymorphisms (for example, single-nucleotide polymorphisms), may render these antigens immunogenic for donor T cells and enable them to evoke alloreactive CTL immunity.
3 Lymphoid-restricted histocompatibility antigen 1 (LRH-1) is an example of a mHAg that has already proven to be a relevant target antigen in the post-transplant setting of AML (Table 1) . 85 This was illustrated by the finding that leukemia patients receiving DLI mounted a functional LRH-1-specific CTL response. 85 Evidence for the in vivo immunogenicity of a particular antigen may also be inferred from the demonstration of naturally occurring antigen-specific immune responses in AML patients. 4 As shown in Table 1 , spontaneous B-cell immune responses have been observed against different AML-associated antigens. Greiner et al. 86 demonstrated that such serological responses could be detected in over one-third of AML patients. 86 Scheibenbogen et al. 87 were the first to describe the natural existence of CD8 þ T-cell immunity against PR1 and WT1 126-134 in patients with AML, both at diagnosis and in complete remission. 87 These findings were corroborated by the later work of Rezvani et al., 73 who observed spontaneous T-cell responses to PR1 and WT1 [126] [127] [128] [129] [130] [131] [132] [133] [134] in two out of eight patients before immunization with a combined PR1/WT1 peptide vaccine. 73 In a separate study, the same group found that such CTL responses were not limited to the immunodominant WT1 [126] [127] [128] [129] [130] [131] [132] [133] [134] epitope, but could also be directed against other HLA-A*0201-restricted WT1-derived epitopes (WT1 [37] [38] [39] [40] [41] [42] [43] [44] [45] , WT1 [187] [188] [189] [190] [191] [192] [193] [194] [195] and WT1 [235] [236] [237] [238] [239] [240] [241] [242] [243] ). 88 A similar observation was made regarding PRAME, which is known to contain at least four different HLA-A*0201-restricted epitopes that can be naturally recognized (PRA [100] [101] [102] [103] [104] [105] [106] [107] [108] , PRA 142-151 , PRA 300-309 and PRA [425] [426] [427] [428] [429] [430] [431] [432] [433] ). 64 According to Greiner et al., 25 up to 70% of AML patients in complete remission spontaneously exhibit circulating PRA 300-309 -specific CTLs, further underscoring the significant natural immunogenicity of PRAME.
25 CD8 þ T cells specific for G250/CAIX [24] [25] [26] [27] [28] [29] [30] [31] [32] , G250/CAIX 254-262 and RHAMM [165] [166] [167] [168] [169] [170] [171] [172] [173] are also regularly detected in the peripheral blood of AML patients, with frequencies of 60%, 13% and 47%, respectively. 25 In a series of 15 AML patients, Siegel et al. 22 observed spontaneous T-cell immune responses to different HLA-A*0201-restricted T-cell epitopes derived from OFA-iLRP, including iLR1 [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] (6/15) 14 These responses range from temporary decreases in leukemic blast counts to the maintenance of complete remission and even the eradication of minimal residual disease.
14 This has been demonstrated by the normalization of WT1 transcript levels in peripheral blood and/or bone marrow samples from patients after WT1-targeted immunization, which is indicative of the achievement of a negative minimal residual disease status. 14, 72 The most striking demonstration of the immunotherapeutic potential of WT1 is provided by the possibility of obtaining stable and complete remissions in patients with active disease through vaccination. 14, 72 Complete remission of AML has also been reported in a number of cases following PR1-targeted active specific immunotherapy, underscoring the clinical value of this peptide for AML immunotherapy. 74 The clinical relevance of PR1 is further supported by the observation of a significant disease-free survival advantage and a trend toward improved overall survival in patients with myeloid malignancies developing immunity to PR1 after peptide immunization. 94 In a clinical trial of combined PR1/WT1 126-134 peptide vaccination, Rezvani et al. 73 demonstrated that the induction of high-avidity PR1-and/or WT1-specific CTLs was critically required to achieve clinical response (reduction of WT1 transcript levels). 73 Schmitt et al. 47 assessed the clinical effectiveness of RHAMM 165-173 peptide vaccination in a mixed cohort of patients with hematological malignancies, including three patients with AML. 47 Immunization was followed by a marked decrease in bone marrow blast counts and a parallel increase in circulating RHAMM 165-173 -tetramer þ effector CD8 þ T cells in one of these patients, showing the potential clinical utility of RHAMM for targeted immunotherapy. 47 A second trial of high-dose RHAMM 165-173 vaccination in nine patients with diverse myeloid malignancies failed to show any clinical benefit in the sole AML patient who was included; three other patients, two with myelodysplastic syndromes and one with myeloma, had variable clinical responses. 95 The potential use of hTERT in active specific immunotherapy for AML is currently under investigation. 96 Preliminary data from a phase I/II clinical trial of hTERT-loaded dendritic cell vaccination in AML patients have suggested an improvement in disease-free survival at 12 months, particularly among patients with a high risk of relapse. 96 Relevance to passive immunotherapy Over the past years, an increasing number of AML antigens have been implicated in the GvL effect associated with allogeneic HSCT or DLI, indicating their therapeutic relevance in the context of passive immunotherapy. 3 Perhaps, the most extensively studied GvL antigens have been mHAgs, such as LRH-1, which is known to serve as a GvL target structure in patients with AML. 3, 85 Because of its hematopoiesis-restricted expression pattern, LRH-1 is considered particularly amenable to induce GvL without detrimental 'on-target' alloimmune reactivity against normal host tissues (that is, graft-versus-host-disease). 84 Unfortunately, the practical applicability of mHAgs for passive immunotherapy is rather limited because of the relative infrequency of mHAg disparities between the donor and recipient, which is a premise for alloimmune recognition, and the low frequencies of some MHC alleles that restrict these antigens. 84 GvL reactions are not limited to mHAgs, but may also be directed against LAAs. The emergence of LAA-specific immune responses after allogeneic HSCT or DLI has been shown to coincide with the induction of clinical responses, suggesting a prominent role of LAAs in mediating GvL. 97 With the exception of one report that questioned the proper functionality of LAAspecific T cells present after allogeneic HSCT, 62 studies have consistently documented the positive impact of LAA-specific immunity on post-transplant clinical outcomes. Several authors have observed decreased relapse rates among transplant patients with myeloid malignancies who develop CTL immunity to PR1. 61, 97 Kapp et al. 61 were able to extend these findings to other LAAs by demonstrating that the risk of post-transplant AML relapse depended on the presence or absence of CTL immunity to PR1, WT1 and/or MUC1. 61 Similarly, Molldrem et al. 78 observed a trend toward a lower relapse rate in allo-transplanted AML patients exhibiting CTL activity to myeloperoxidase. 78 Recently, Wadia et al. 46 unveiled a positive correlation between NuSAP1 antibody development and reduced risk of AML relapse after allogeneic HSCT, implicating a humoral immune response to NuSAP1 in the GvL effect. 46 Durable remissions of CML have been linked to the development of humoral and/or cellular immune responses to CML28 (ref. 80) and CML66 (refs 81,82) following DLI for post-transplant CML relapse. Immunity to BMI1 was correlated with improved outcomes after allogeneic HSCT in CML. 83 Given that they are known to be overexpressed in AML, it is conceivable that CML28, CML66 and BMI1 could as well contribute to GvL in the context of allogeneic HSCT for AML.
A possible correlation between the emergence of CTL immunity after allogeneic HSCT and long-term disease remission has also been suggested for several CTAs, including members of the MAGE family and RAGE-1. 79 Amir et al. 27 recently postulated that allo-HLA-restricted T cells specific to PRAME could contribute to a selective GvL effect after HLA-mismatched HSCT. Allo-restricted PRAME-specific T cells indeed appeared to be highly reactive to AML cells, but not to classical graft-versus-host-disease tissues (that is, skin, liver and gut), suggesting that PRAME may be an attractive target antigen for dissociating GvL from GvH responses. 27 
CONCLUSIONS
The past decade has witnessed a surge in the number of identified AML-related antigens that could serve as target structures for antileukemia immune responses. Combined with the fast pace at which additional antigens are being discovered, this progress opens up new possibilities for targeted immunotherapy of AML, while also raising the difficult question about which candidate antigens should be prioritized for future investigation. 4 In this review, in an effort to help this selection process, we aimed to provide a comprehensive overview of all hitherto identified candidate target antigens for AML immunotherapy and to review their potential benefits and limitations.
